Bordetella pertussis vaccine strains and circulating isolates in Serbia

Vaccine

Volumn 28, Issue 5, 2010, Pages 1188-1192

  Dakic, Gordana ^a   Kallonen, Teemu ^b,c   Elomaa, Annika ^b   Pljesa, Tatjana ^a   Vignjevic Krastavcevic, Mirjana ^a   He, Qiushui ^b,c  

^a Institute of Virology Vaccines and Sera Torlak   (Serbia)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Bordetella pertussis; Pertussis; Vaccine

Indexed keywords

FIMBRIA PROTEIN; FIMBRIA PROTEIN 2; FIMBRIA PROTEIN 2.3; FIMBRIA PROTEIN 3; PERTACTIN; PERTACTIN 1; PERTACTIN 11; PERTACTIN 2; PERTACTIN 3; PERTUSSIS TOXIN; PERTUSSIS TOXIN A1; PERTUSSIS TOXIN A2; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; INFANT; NONHUMAN; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PULSED FIELD GEL ELECTROPHORESIS; SCHOOL CHILD; SERBIA; SEROPREVALENCE; SEROTYPE; SEROTYPING;

ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PERTUSSIS VACCINE; SERBIA; SEROTYPING; WHOOPING COUGH;

EID: 74249114793     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.036     Document Type: Article

References (21)

1. He Q., and Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol June (3) (2008) 329-339
2. Celentano L.P., Massari M., Paramatti D., Salmaso S., and Tozzi A.E. Resurgence of pertussis in Europe. Pediatr Infect Dis J 24 September (9) (2005) 761-765
3. Halperin S.A. The control of pertussis-2007 and beyond. N Engl J Med 356 January (2) (2007) 110-113
4. McIntyre P., Gidding H., Gilmour R., Lawrence G., Hull B., Horby P., et al. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell May (Suppl.) (2002) i-xi, 1-111
5. Mooi F.R., van Loo I.H., and King A.J. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?. Emerg Infect Dis Suppl. 7 3 (2001) 526-528
6. WHO. World Health Organisation: immunization, vaccination and biologicals. Vaccine preventable diseases Vaccines monitoring system 2009 Global Summary Reference Time Series: SERBIA http://www.who.int/immunization_monitoring/en/globalsummary/timeseries/t scoveragebycountry.cfm?C=SRB.
7. Mooi F.R., Hallander H., Wirsing von Konig C.H., Hoet B., and Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis 19 March (3) (2000) 174-181
8. Advani A., Donnelly D., and Hallander H. Reference system for characterization of Bordetella pertussis pulsed-field gel electrophoresis profiles. J Clin Microbiol 42 July (7) (2004) 2890-2897
9. Elomaa A., Advani A., Donnelly D., Antila M., Mertsola J., Hallander H., et al. Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol 43 August (8) (2005) 3681-3687
10. Heikkinen E., Xing D.K., Olander R.M., Hytonen J., Viljanen M.K., Mertsola J., et al. Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol 8 (2008) 162
11. Cassiday P., Sanden G., Heuvelman K., Mooi F., Bisgard K.M., and Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 182 November (5) (2000) 1402-1408
12. Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G., Gaastra W., and Willems R.J. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 66 February (2) (1998) 670-675
13. Leininger E., Roberts M., Kenimer J.G., Charles I.G., Fairweather N., Novotny P., et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci USA 88 January (2) (1991) 345-349
14. Weber C., Boursaux-Eude C., Coralie G., Caro V., and Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 39 December (12) (2001) 4396-4403
15. Poynten M., McIntyre P.B., Mooi F.R., Heuvelman K.J., and Gilbert G.L. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol Infect 132 April (2) (2004) 185-193
16. Hallander H.O., Advani A., Donnelly D., Gustafsson L., and Carlsson R.M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 43 June (6) (2005) 2856-2865
17. Preston N.W., and Carter E.J. Serotype specificity of vaccine-induced immunity to pertussis. Commun Dis Rep CDR Rev 2 December (13) (1992) R155-R156
18. Hallander H., Advani A., Riffelmann M., von Konig C.H., Caro V., Guiso N., et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol 45 October (10) (2007) 3257-3262
19. King A.J., Berbers G., van Oirschot H.F., Hoogerhout P., Knipping K., and Mooi F.R. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147 November (Pt 11) (2001) 2885-2895
20. Bottero D., Gaillard M.E., Fingermann M., Weltman G., Fernandez J., Sisti F., et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol 14 November (11) (2007) 1490-1498
21. Pereira A., Pereira A.S., Moreira-Filho C.A., Bando S.Y., and Tambourgi D.V. Comparative analysis of a Bordetella pertussis patient isolated strain and classical strains used in the pertussis vaccine. Vaccine 23 July (34) (2005) 4353-4358